Skip to main content
IMA
NASDAQ Life Sciences

OrbiMed Advisors, a Director, Invests $3.75M in ImageneBio Private Placement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$5.78
Mkt Cap
$64.649M
52W Low
$3.94
52W High
$216
52W Position info
47% above low
Off High info
97% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

IMA sits 47% above its 52-week low of $3.94 on light trading volume (0.2× avg).

Summary

OrbiMed Advisors, an institutional investor with a board seat, acquired $3.75 million in pre-funded warrants as part of ImageneBio's recently announced private placement, signaling strong confidence.


Key Events · Ownership and Investor Activity · IMA

  • Institutional Director Invests

    OrbiMed Advisors, an institutional investor and director, acquired 721,292 pre-funded warrants.

  • Significant Capital Infusion

    The purchase represents a $3.75 million investment, part of the company's recent $30 million private placement.

  • Strong Vote of Confidence

    This substantial investment from a key backer signals strong confidence in ImageneBio's future.


Analysis · IMA · Life Sciences

This Form 4 details the participation of OrbiMed Advisors, an institutional investor and director, in ImageneBio's $30 million private placement announced on April 13, 2026. OrbiMed acquired 721,292 pre-funded warrants for approximately $3.75 million. This significant investment, representing about 5.8% of the company's market capitalization, demonstrates strong conviction from a key institutional backer and provides crucial capital for the micro-cap biotech company. The purchase price of $5.199 per warrant aligns with the terms of the broader capital raise.

How filings like this one have moved

In the 30 days to Sep 20, 2026, 38.8% of the 340 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMA was trading at $5.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $64.6M. The 52-week trading range was $3.94 to $216.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMA - Latest Insights

IMA
Aug 05, 2026, 4:22 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $4.89 info
Change: -$0.860 (-15%) info
Market Cap: $55.509M info
IMA
Aug 05, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.71
Real-time Price: $4.89 info
Change: -$0.820 (-14%) info
Market Cap: $55.509M info
IMA
Aug 05, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.71
Real-time Price: $4.89 info
Change: -$0.820 (-14%) info
Market Cap: $55.509M info
IMA
Aug 05, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.71
Real-time Price: $4.89 info
Change: -$0.820 (-14%) info
Market Cap: $55.509M info
IMA
Jul 23, 2026, 4:28 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $5.57
Real-time Price: $4.89 info
Change: -$0.680 (-12%) info
Market Cap: $55.509M info